Market Overview

Pulmonary Embolism Drug Development Pipeline Analysis Report 2018 -


The "2018
Pulmonary Embolism Drug Development Pipeline Analysis Report- Companies,
Drugs, Clinical Trials, Latest Developments in Pulmonary Embolism Market"

report has been added to's

Pulmonary Embolism refers to a heart condition in the arteries
transporting blood to the lungs are blocked, causing sudden shortness of
breath and chest pain. The prevalence rates in the US are around 0.08%.
Clinical symptoms of the disease include pulse less electrical activity
to mild dyspnea. On the basis of severity, Pulmonary Embolism is
classified as massive, sub-massive and low types. Anticoagulants are
primarily administered to the patients.

To assist researchers, investors and business development managers, the
publisher has come up with a comprehensive report on Pulmonary Embolism
pipeline. The report provides insights into different therapeutic
candidates in preclinical, research, discovery, NDA/IND, pre
registration, phase 1, phase 2, and phase 3 trials). Drugs under
development directly and through combination with other drugs are also

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Pulmonary Embolism
pipeline product. Mechanism of Action and the target area of the
pipeline product are also provided. Further, clinical and preclinical
trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key
trends in Pulmonary Embolism pipeline studies. The products under
development are categorized according to their development phase,
mechanism and company to provide detailed insights into the type of
drugs being developed and the stages of development.

Companies Mentioned

  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings
  • ST Pharm Co.,Ltd.
  • Tasly Phar. International Co., Ltd
  • TeaRx Ltd.
  • Verseon Corp

Key Topics Covered:

1 Table of Contents

2 Pulmonary Embolism Pipeline Analysis

3 Pulmonary Embolism- Company Wise Pipeline Analysis

4 Pulmonary Embolism R&D Pipeline Snapshots

5 Recent Developments in Pulmonary Embolism Pipeline

6 Appendix

For more information about this report visit

View Comments and Join the Discussion!